Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Overview
Date Founded

1933

Headquarters

345 Park Avenue,New York, NY 10154

Type of Company

Public

Employees (Worldwide)

30K

Industries

Pharmaceuticals
Medical Support Services
Hospitals & Patient Services
Biotechnology

Company Description

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Contact Data
Trying to get in touch with decision makers at Bristol-Myers Squibb Company? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman of the Board & Chief Executive Officer

Head, Corporate & Employee Communications

Chief Financial Officer, Treasurer & Vice President

Chief Financial Officer & Executive Vice President

Executive Vice President & Chief Financial Officer

Executive Vice President, General Counsel

Chief Marketing Officer

Executive Vice President & Chief Commercial Officer

Executive Vice President & Chief Information Officer

Chief Scientific Officer & Executive Vice President

Board of Directors

Former Chairman of the Board & Chief Executive Officer at Bristol-Myers Squibb Company

N at Accenture LLP

Co-Director of the Wills Vision Research Center at Thomas Jefferson University

Former President & Chief Financial Officer at Bausch + Lomb, Inc.

Executive Officer, Director at Adolor Corp.

Former Acting Chief Executive Officer at Eli Lilly & Company

Former Chief Executive Officer at OraPharma, Inc.

Advisory Partner at Bain & Co., Inc.

Chairman & Co-Founder at Vir Biotechnology, Inc.

Former President & Chief Executive Officer at Vertex Pharmaceuticals, Inc.

Paths to Bristol-Myers Squibb Company
Potential Connections via
Relationship Science
You
Bristol-Myers Squibb Company
Owners & Shareholders
Details Hidden

WMC relies on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macro-analysts, quantitative analysts and technical analysts. WMC’s portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team’s investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR’s or its affiliates’ central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

Renaissance Technologies LLC is an investment management company dedicated to producing superior returns for its clients and employees by adhering to mathematical and statistical methods.

Recent Transactions
Details Hidden

Catalent, Inc. purchases Bristol-Myers Squibb Co. /Anagni Manufacturing Facility from Bristol-Myers Squibb Company

Details Hidden

Bristol-Myers Squibb Company purchases Celgene Corp.

Details Hidden

SK Holdings Co., Ltd., SK Biotek, Inc. purchase Bristol Myers Squibb Co /Pharmaceutical Facility from Bristol-Myers Squibb Company

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onBristol-Myers Squibb Company purchases DuPont Pharmaceuticals Co. from DuPont

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Accountant

Advised onBristol-Myers Squibb Company purchases DuPont Pharmaceuticals Co. from DuPont

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Amylin Pharmaceuticals, Inc.

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Advisors & Consultants
Legal Advisor

Partner at Sidley Austin LLP

Legal Advisor

Shareholder at Greenberg Traurig LLP

Advisor

Senior Advisor at Essex Woodlands Management, Inc.

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Key Stats and Financials As of 2019
Market Capitalization
$134B
Total Enterprise Value
$142B
Earnings Per Share
$2.01
Revenue
$26.1B
Net Profit
$3.44B
EBITDA
$8.25B
EBITDAMargin
31.55%
Total Debt
$47.5B
Total Equity
$51.7B
Enterprise Value Sales
5.44x
Enterprise Value EBITDAOperating
17.14x
TEVNet Income
41.33x
Debt TEV
0.33x
Three Year Compounded Annual Growth Rate Of Revenue
10.41%
Five Year Compounded Annual Growth Rate Of Revenue
10.49%
Non-Profit Donations & Grants
$500 +
2019
$10K - $25K
2019
Non-Profit Donations & Grants Received
Political Donations
$500
2012
$250
2012
$500
2011
Investments
Details Hidden

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

Details Hidden

Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA.

Details Hidden

JW Therapeutics (Shanghai) Co., Ltd. engages in biopharmaceutical industry. It focuses on the development, transformation, and promotion of cell-based immunotherapies to treat cancer. The company was founded by Yi Ping Li on February 18, 2016 and is headquartered in Shanghai, China.

Investors
Details Hidden

Managing Director at Lehman Brothers Europe Ltd.

Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Co-Founder at Starboard Value LP

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

TSR, Inc. Auto Parts & Tires | Hauppauge, NY

TSR, Inc. engages in the provision of contract computer programming and staffing services. It supports its clients with technical computer personnel to supplement their in-house information technology capabilities. The company was founded in 1969 and is headquartered in Hauppauge, NY.

Portola Pharmaceuticals, Inc. Pension Funds & Sovereign Wealth | South San Francisco, CA

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Awards & Honors
Rank #168
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #168
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bristol-Myers Squibb Company. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bristol-Myers Squibb Company's profile does not indicate a business or promotional relationship of any kind between RelSci and Bristol-Myers Squibb Company.